WAO/EAACI 2021 Guidelines: Select Recommendations in Adults
In 2022, the World Allergy Organization (WAO) in collaboration with the European Academy of Allergy and Clinical Immunology (EAACI) published an update and revision to their global guideline for HAE. An international expert panel was convened to review the existing evidence and developed recommendations with the goal of providing clinicians and their patients with guidance that will assist them in making rational decisions in the management of Type 1 and Type 2 HAE. Read the full Guideline.
On-Demand Treatment: All Attacks Are Considered for On-demand Treatment
Early treatment with C1-INH concentrate, ecallantide, or Icatibant Injection provides a better treatment response than late treatment. Early treatment is associated with a shorter time to resolution of symptoms and shorter total attack duration regardless of attack severity. As early treatment is facilitated by self-administration, all patients with HAE Types 1 or 2 should be considered for home therapy and self-administration training. All C1-INH concentrates and icatibant are licensed for self-administration, although approved product indications vary around the world.8 It is recommended that all patients have sufficient medication for on-demand treatment of two attacks and carry on-demand medication at all times.
